Krystal Biotech (KRYS) – Investment Analysts’ Recent Ratings Updates

Krystal Biotech (NASDAQ: KRYS) has recently received a number of price target changes and ratings updates:

• 2/25/2026 – Krystal Biotech had its price target raised by Guggenheim from $224.00 to $284.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Krystal Biotech was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 2/18/2026 – Krystal Biotech had its price target raised by Citigroup Inc. from $336.00 to $371.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Krystal Biotech had its price target raised by Chardan Capital from $220.00 to $323.00. They now have a “buy” rating on the stock.
• 2/17/2026 – Krystal Biotech had its price target raised by Jefferies Financial Group Inc. from $310.00 to $371.00. They now have a “buy” rating on the stock.
• 2/5/2026 – Krystal Biotech was downgraded by Zacks Research from “strong-buy” to “hold”.
• 1/30/2026 – Krystal Biotech had its price target raised by The Goldman Sachs Group, Inc. from $206.00 to $327.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Krystal Biotech had its price target raised by Bank of America Corporation from $288.00 to $318.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Krystal Biotech had its price target raised by Citigroup Inc. from $320.00 to $336.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Krystal Biotech had its “buy” rating reaffirmed by TD Cowen.
• 1/9/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock, up from $240.00.
• 1/9/2026 – Krystal Biotech had its price target raised by TD Cowen from $202.00 to $306.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Krystal Biotech was upgraded by Zacks Research from “hold” to “strong-buy”.
• 1/6/2026 – Krystal Biotech was upgraded by Citigroup Inc. from “neutral” to “buy”. They now have a $309.00 price target on the stock, up from $198.00.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the transaction, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dino A. Rossi sold 18,950 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $261.41, for a total value of $4,953,719.50. Following the transaction, the director directly owned 78,691 shares of the company’s stock, valued at $20,570,614.31. This represents a 19.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 116,611 shares of company stock valued at $30,008,839. Insiders own 13.70% of the company’s stock.

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.